carmustine has been researched along with Leukemia P388 in 10 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i." | 1.28 | L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ( Dykes, D; Malspeis, L; Plowman, J; Waud, W; Zaharko, D, 1992) |
| "Carmethizole activity was similar to that of melphalan across the murine solid tumor panel, which consisted of B16 melanoma; colon adenocarcinomas 11a, 26, and 36; and the KHT sarcoma." | 1.28 | In vivo and in vitro evaluation of the alkylating agent carmethizole. ( Anderson, WK; Elliott, WL; Fry, DW; Hawkins, PA; Hook, KE; Leopold, WR; Nelson, JM, 1991) |
| " Dose-response studies showed that L-histidinol conferred dose-dependent, synergistic improvements on the capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukemia." | 1.28 | L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia. ( Fang, WD; Warrington, RC, 1989) |
| "Positive therapeutic effects of interferons (IFNs) in combination with other therapies will depend on defining modalities, doses, and timing of treatment in the setting of varied tumor burdens." | 1.27 | Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. ( Borden, EC; Bryan, GT; Hatcher, JF; Sidky, YA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (70.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinkam, RJ | 1 |
| Dolan, ME | 1 |
| Umeda, Y | 1 |
| Sakamoto, A | 1 |
| Nakamura, J | 1 |
| Ishitsuka, H | 1 |
| Yagi, Y | 1 |
| Zaharko, D | 1 |
| Plowman, J | 1 |
| Waud, W | 1 |
| Dykes, D | 1 |
| Malspeis, L | 1 |
| Elliott, WL | 1 |
| Fry, DW | 1 |
| Anderson, WK | 1 |
| Nelson, JM | 1 |
| Hook, KE | 1 |
| Hawkins, PA | 1 |
| Leopold, WR | 1 |
| Gessner, T | 1 |
| Vaughan, LA | 1 |
| Beehler, BC | 1 |
| Bartels, CJ | 1 |
| Baker, RM | 1 |
| Dorr, RT | 1 |
| Soble, MJ | 1 |
| Warrington, RC | 2 |
| Fang, WD | 2 |
| Dimmock, JR | 1 |
| Jonnalagadda, SS | 1 |
| Leek, DM | 1 |
| Borden, EC | 1 |
| Sidky, YA | 1 |
| Hatcher, JF | 1 |
| Bryan, GT | 1 |
| Kramer, RA | 1 |
| Zakher, J | 1 |
| Kim, G | 1 |
10 other studies available for carmustine and Leukemia P388
| Article | Year |
|---|---|
An analysis of 1-(2-chloroethyl)-1-nitrosourea activity at the cellular level.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Survival; Drug Evaluation, Preclinical; Ethylnitros | 1983 |
Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.
Topics: Animals; Carmustine; Fluorouracil; Immunosuppression Therapy; Killer Cells, Natural; Leukemia L1210; | 1983 |
L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Hi | 1992 |
In vivo and in vitro evaluation of the alkylating agent carmethizole.
Topics: Animals; Antineoplastic Agents; Carmustine; DNA Repair; DNA, Neoplasm; Drug Screening Assays, Antitu | 1991 |
Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells.
Topics: Animals; Carbon Dioxide; Carmustine; Cell Survival; Daunorubicin; Doxorubicin; Drug Resistance; Gluc | 1990 |
H2-antagonists and carmustine.
Topics: Animals; Bone Marrow; Carmustine; Cimetidine; Drug Synergism; Histamine H2 Antagonists; Leukemia P38 | 1989 |
L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; C | 1989 |
Evaluation of Mannich bases of styryl ketones and related hydrazones for activity against P388 leukemia.
Topics: Animals; Carmustine; Drug Evaluation, Preclinical; Female; Hydrazones; Ketones; Leukemia P388; Leuke | 1988 |
Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Administ | 1988 |
Role of the glutathione redox cycle in acquired and de novo multidrug resistance.
Topics: Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Resistance; Glutathione; Glutathione Perox | 1988 |